

DAFTAR PUSTAKA

- Aslantürk, Ö. S. 2018, 'In Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages'. *Genotoxicity - A Predictable Risk to Our Actual World*, pp. 1–18. <https://doi.org/10.5772/intechopen.71923>.
- Assi, S., Torrington, E., Cheema, E., & Hamid, A. Al. 2021, 'Adverse drug reactions associated with chemotherapeutic agents used in breast cancer: Analysis of patients' online forums'. *Journal of Oncology Pharmacy Practice*, vol. 27(1), pp. 108–118. <https://doi.org/10.1177/1078155220915767>.
- Balasubramanian, R., Iqbal, H., Gopal, R. V., & Baby, C. 2013, 'Synthesis and preliminary evaluation of a focused chalcone library for anti-inflammatory activity'. *Indian Journal of Pharmaceutical Education and Research*, vol. 47(4), pp. 31–38. <https://doi.org/10.5530/ijper.47.4.5>.
- Bertl, H. Becker, T. Eicher, C. Herhaus, G. Kapadia, H. Bartsch, C. Gerhauser. 2004, 'Inhibition of endothelial cell functions by novel potential cancer chemopreventive agents'. *Biochem. Biophys. Res. Commun.* 325 (2004) 287e295.
- Boncler, M., Rózalski, M., Krajewska, U., Podswdek, A., & Watala, C. 2014, 'Comparison of PrestoBlue and MTT assays of cellular viability in the assessment of anti-proliferative effects of plant extracts on human endothelial cells'. *Journal of Pharmacological and Toxicological Methods*, vol. 69(1), pp. 9–16. <https://doi.org/10.1016/j.vascn.2013.09.003>.
- Bustos, L., Echiburú-Chau, C., Castro-Alvarez, A., Bradshaw, B., Simirgiotis, M. J., Mellado, M., Parra, C., & Cuellar, M. 2022. 'Cytotoxic Effects on Breast Cancer Cell Lines of Chalcones Derived from a Natural Precursor and Their Molecular Docking Analysis'. *Molecules*, vol. 27(14), pp. 1–10. <https://doi.org/10.3390/molecules27144387>.
- Chen, S. H., & Chang, J. Y. 2019, 'New insights into mechanisms of cisplatin resistance: From tumor cell to microenvironment'. *International Journal of Molecular Sciences*, vol. 20(17). <https://doi.org/10.3390/ijms20174136>
- Comşa, Ş., Cîmpean, A. M., & Raica, M. 2015, 'The story of MCF-7 breast cancer cell line: 40 Years of experience in research'. *Anticancer Research*, vol. 35(6), pp. 3147–3154.
- Damasuri, Eti Nurwening Sholikhah, & Mustofa. 2020, 'Cytotoxicity of ((E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one)) on HeLa cell line'. *Indonesian Journal of Pharmacology and Therapy*, vol. 1(2), pp. 54–59. <https://doi.org/10.22146/ijpther.606>.
- Diehl, B. 2008, 'Principles in NMR spectroscopy'. *NMR Spectroscopy in Pharmaceutical Analysis*, pp. 1–41. <https://doi.org/10.1016/B978-0-444-53173-5.00001-9>.
- Fikroh, R. A. 2018, 'Sintesis dan Uji Aktivitas Senyawa 2-bromo-4,5-

- dimetoksikalkon Terhadap Sel Kanker T47D Secara In Vitro'. *Journal of Pharmaceutical Science and Medical Research*, vol. 1(1), pp. 37. <https://doi.org/10.25273/pharmed.v1i1.2269>.
- Fikroh, R. A., Matsjeh, S., & Anwar, C. 2020, 'Synthesis and anticancer activity of (E)-2'-hydroxy-2-bromo-4,5-dimethoxychalcone against breast cancer (MCF-7) cell line'. *Molekul*, vol. 15(1), pp. 34–39. <https://doi.org/10.20884/1.jm.2020.15.1.558>.
- Fogaça, T. B., Martins, R. M., Begnini, K. R., Carapina, C., Ritter, M., de Pereira, C. M. P., Seixas, F. K., & Collares, T. 2017, 'Apoptotic effect of chalcone derivatives of 2-acetyl thiophene in human breast cancer cells'. *Pharmacological Reports: PR*, vol. 69(1), pp. 156–161. <https://doi.org/10.1016/j.pharep.2016.10.003>.
- Gunawan, R., & Nandiyanto, A. B. D. 2021, 'How to read and interpret 1h-NMR and 13c-NMR spectrums'. *Indonesian Journal of Science and Technology*, vol. 6(2), pp. 267–298. <https://doi.org/10.17509/ijost.v6i2.34189>.
- Guo, L., Zhang, H., Tian, M., Tian, Z., Xu, Y., Yang, Y., Peng, H., Liu, P., & Liu, Z. 2018, 'Electronic effects on reactivity and anticancer activity by half-sandwich N, N-chelated iridium(iii) complexes. *New Journal of Chemistry*, vol. 42(19), pp. 16183–16192. <https://doi.org/10.1039/C8NJ03360A>.
- Hill, D. P., Harper, A., Malcolm, J., McAndrews, M. S., Mockus, S. M., Patterson, S. E., Reynolds, T., Baker, E. J., Bult, C. J., Chesler, E. J., & Blake, J. A. 2019, 'Cisplatin-resistant triple-negative breast cancer subtypes: Multiple mechanisms of resistance'. *BMC Cancer*, vol. 19(1), pp. 1–13. <https://doi.org/10.1186/s12885-019-6278-9>.
- Irfan, R., Mousavi, S., Alazmi, M., & Saleem, R. S. Z. 2020, 'A comprehensive review of aminochalcones'. *Molecules*, vol. 25(22). <https://doi.org/10.3390/molecules25225381>.
- Kementrian Kesehatan Republik Indonesia. 2018, *Panduan Penatalaksanaan Kanker Payudara. Komite Penanggulangan Kanker Nasional*. Diakses melalui <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf>.
- Khairul, W. M., Hashim, F., Mohamed, M., Shah, N. S. M. N., Johari, S. A. T. T., Rahamathullah, R., Daud, A. I., & Ma, N. L. 2021, 'Synthesis, Molecular Docking and Biological Activity Evaluation of Alkoxy Substituted Chalcone Derivatives: Potential Apoptosis Inducing Agent on MCF-7 Cells'. *Anti-Cancer Agents in Medicinal Chemistry*, pp. 1–13. <https://doi.org/10.3389/conf.fphar.2018.63.00123>.
- Krippendorff, B. F., Lienau, P., Reichel, A., & Huisinga, W. 2007, 'Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery'. *Journal of Biomolecular Screening*, vol. 12(1), pp. 92–99. <https://doi.org/10.1177/1087057106295897>.
- Lall, N., Henley-Smith, C. J., De Canha, M. N., Oosthuizen, C. B., & Berrington, D. 2013, 'Viability reagent, presto blue, in comparison with other available

- reagents, utilized in cytotoxicity and antimicrobial assays'. *International Journal of Microbiology*, <https://doi.org/10.1155/2013/420601>.
- Lee, A. V., Oesterreich, S., & Davidson, N. E. 2015, 'MCF-7 Cells - Changing the Course of Breast Cancer Research and Care for 45 Years'. *Journal of the National Cancer Institute*, vol. 107(7), pp. 1–4. <https://doi.org/10.1093/jnci/djv073>.
- Li, W., Zhou, J., & Xu, Y. 2015, ' Study of the in vitro cytotoxicity testing of medical devices'. *Biomedical Reports*, vol. 3(5), pp. 617–620. <https://doi.org/10.3892/br.2015.481>.
- Liew, S. K., Malagobadan, S., Arshad, N. M., & Nagoor, N. H. 2020, 'A review of the structure-activity relationship of natural and synthetic antimetastatic compounds'. *Biomolecules*, vol. 10(1), pp. 1–28. <https://doi.org/10.3390/biom10010138>.
- Luzak, B., Siarkiewicz, P., & Boncler, M. 2022, 'An evaluation of a new high-sensitivity PrestoBlue assay for measuring cell viability and drug cytotoxicity using EA.hy926 endothelial cells'. *Toxicology in Vitro*, vol. 83, pp. 105407. <https://doi.org/10.1016/j.tiv.2022.105407>.
- Mahapatra, D. K., Bharti, S. K., & Asati, V. 2015, 'Anti-cancer chalcones: Structural and molecular target perspectives'. *European Journal of Medicinal Chemistry*, vol. 98, pp. 69–114. <https://doi.org/10.1016/j.ejmech.2015.05.004>.
- Mai, C. W., Yaeghoobi, M., Abd-Rahman, N., Kang, Y. B., & Pichika, M. R. 2014, 'Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL-resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins'. *European Journal of Medicinal Chemistry*, vol. 77, pp. 378-387.
- Mphahlele, M. J., Maluleka, M. M., Parbhoo, N., & Malindisa, S. T. 2018, 'Synthesis, evaluation for cytotoxicity and molecular docking studies of Benzo[c]furan-chalcones for potential to inhibit Tubulin polymerization and/or EGFR-tyrosine kinase phosphorylation.' *International Journal of Molecular Sciences*, vol. 19(9), pp. 1–18. <https://doi.org/10.3390/ijms19092552>.
- Pavia, D. L., Lampman, G. M., Kriz, G. S., & Vyvyan, J. R. 2016. Introduction to spectroscopy.
- Prabhakar, Ranganathan Balasubramanian, Priyanka Sathe, C. Murali Krishna, A. J. 2014, 'In Vitro Anticancer Activity of Monosubstituted Chalcone Derivatives'. *International Journal of Tumor Therapy*, vol. 3(1), pp. 1–9. <https://doi.org/10.5923/j.ijtt.20140301.01>.
- Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J., & Ruiz-Frutos, C. 2020, 'Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer'. *Medicine*, vol. 99(33), e21695. <https://doi.org/10.1097/MD.00000000000021695>.

- Puspita, N. A., & Bedford, A. 2017, 'Morphological Changes of Cisplatin-resistant Human Breast Cancer MCF-7 Cell Line'. *International Journal of Integrated Health Sciences*, vol. 5(1), pp. 8–14. <https://doi.org/10.15850/ijih.v5n1.960>.
- Sharma, A. Chaudhary, S. Arora, A.K. Saxena, M. Paul, S. Ishar. 2013, ' β -Ionone derived chalcones as potent antiproliferative agents', *Eur. J. Med. Chem.* vol. 69 310e315.
- Shen, D. W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. 2012, 'Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes'. *Pharmacological Reviews*, vol. 64(3), pp. 706–721. <https://doi.org/10.1124/pr.111.005637>.
- Shen, K. H., Chang, J. K., Hsu, Y. L., & Kuo, P. L. 2007, 'Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signaling in human bladder cancer cells'. *Basic and Clinical Pharmacology and Toxicology*, vol. 101(4), pp. 254–261. <https://doi.org/10.1111/j.1742-7843.2007.00120.x>.
- Shenoy, N., Stenson, M., Lawson, J., Abeykoon, J., Patnaik, M., Wu, X., & Witzig, T. 2017, 'Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells'. *Laboratory Investigation*, vol. 97(5), pp. 494–497. <https://doi.org/10.1038/labinvest.2017.18>.
- Srisawat, T., Chumkaew, P., Heed-Chim, W., Sukpondma, Y., & Kanokwiroon, K. 2013, 'Phytochemical screening and cytotoxicity of crude extracts of vatica diospyroides Symington type LS'. *Tropical Journal of Pharmaceutical Research*, vol. 12(1), pp. 71–76. <https://doi.org/10.4314/tjpr.v12i1.12>.
- Stompor, M., Kałużny, M., & Żarowska, B. 2016, 'Biotechnological methods for chalcone reduction using whole cells of Lactobacillus, Rhodococcus and Rhodotorula strain as a way to produce new derivatives'. *Applied Microbiology and Biotechnology*, vol. 100(19), pp. 8371–8384. <https://doi.org/10.1007/s00253-016-7607-4>.
- Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., & Zhu, H. P. 2017, 'Risk factors and preventions of breast cancer'. *International Journal of Biological Sciences*, vol. 13(11), pp. 1387–1397. <https://doi.org/10.7150/ijbs.21635>.
- Susanti, E. V. H., & Setyowati, W. A. E. 2019, 'Synthesis and Characterization of Some Bromochalcones Derivatives'. *IOP Conference Series: Materials Science and Engineering*, vol. 578(1). <https://doi.org/10.1088/1757-899X/578/1/012002>.
- Syam, S., Abdelwahab, S. I., Al-Mamary, M. A., & Mohan, S. 2012, 'Synthesis of chalcones with anticancer activities'. *Molecules*, vol 17(6), pp. 6179–6195. <https://doi.org/10.3390/molecules17066179>.
- Vantangoli, M. M., Madnick, S. J., Huse, S. M., Weston, P., & Boekelheide, K. 2015, 'MCF-7 human breast cancer cells form differentiated microtissues in

scaffold-free hydrogels'. *PLoS ONE*, vol. 10(8), pp. 1–20. <https://doi.org/10.1371/journal.pone.0135426>.

Wijayanti, L. W., Swasono, R. T., Lee, W., & Jumina, J. 2021, 'Synthesis and Evaluation of Chalcone Derivatives as Novel Sunscreen Agent'. *Molecules*, vol. 26(9), 2698.

Xu, M., McCanna, D. J., & Sivak, J. G. 2015, 'Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the viability of human corneal epithelial cells'. *Journal of Pharmacological and Toxicological Methods*, vol. 71, pp. 1–7. <https://doi.org/10.1016/j.vascn.2014.11.003>.

Yamali, C., Gul, H. I., Sakagami, H., & Supuran, C. T. 2016, 'Synthesis and bioactivities of halogen bearing phenolic chalcones and their corresponding bis Mannich bases'. *Journal of Enzyme Inhibition and Medicinal Chemistry*, vol. 31, pp. 125–131. <https://doi.org/10.1080/14756366.2016.1221825>.

Zhang, S., Li, T., Zhang, Y., Xu, H., Li, Y., Zi, X., Yu, H., Li, J., Jin, C., & Liu, H. M. 2016, 'A new brominated chalcone derivative suppresses the growth of gastric cancer cells in vitro and in vivo involving ROS mediated up-regulation of DR5 and 4 expressions and apoptosis'. *Toxicol Appl Pharmacol*, vol. 309, pp. 77–86. <https://doi.org/10.1016/j.taap.2016.08.023.A>.

